Which combination is typically used in the initial management of immune thrombocytopenia?

Which combination is typically used in the initial management of immune thrombocytopenia?

• A. Prednisone and IVIG
• B. Platelet transfusion alone
• C. Splenectomy
• D. Thrombopoietin receptor agonists as first-line

Answer: (A)

Immune thrombocytopenia involves autoantibody‑driven destruction of platelets, so initial management focuses on stopping the immune attack and boosting platelet numbers quickly to reduce bleeding risk. Corticosteroids like prednisone cut antibody production and blunt the immune clearance of platelets, while IVIG blocks the Fc receptors on macrophages that normally remove opsonized platelets from circulation. Together, they provide a rapid rise in platelet count and a more durable response as the immune process is dampened. Platelet transfusions alone aren’t usually effective in ITP because the transfused platelets are rapidly destroyed by the same immune mechanism. Splenectomy is typically reserved for patients who do not respond to medical therapy, since it removes the primary site of platelet destruction but isn’t a first‑line option. Thrombopoietin receptor agonists lift platelet production but are generally used after first‑line treatments fail or in select situations.

Immune thrombocytopenia involves autoantibody‑driven destruction of platelets, so initial management focuses on stopping the immune attack and boosting platelet numbers quickly to reduce bleeding risk. Corticosteroids like prednisone cut antibody production and blunt the immune clearance of platelets, while IVIG blocks the Fc receptors on macrophages that normally remove opsonized platelets from circulation. Together, they provide a rapid rise in platelet count and a more durable response as the immune process is dampened. Platelet transfusions alone aren’t usually effective in ITP because the transfused platelets are rapidly destroyed by the same immune mechanism. Splenectomy is typically reserved for patients who do not respond to medical therapy, since it removes the primary site of platelet destruction but isn’t a first‑line option. Thrombopoietin receptor agonists lift platelet production but are generally used after first‑line treatments fail or in select situations.